Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

The mRNA treatment landscape is shaping up to be competitive, but the market is also nascent, with the covid pandemic marking the first commercial product from Moderna, the industry leader.

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

With only one commercial product – the COVID-19 vaccine – Moderna faces pressure to diversify its pipeline rapidly. As the company invests heavily in expanding its non-COVID mRNA vaccine ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

The patent has also been contested by Sanofi, which was also developing an mRNA-based COVID-19 vaccine ... led to a traditional private commercial model. Moderna and Pfizer/BioNTech have both ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands among Wednesday’s worst-performing stocks. The stock market declined on Wednesday, with all major indices ...

The virus was confirmed on Friday at a commercial poultry production ... preliminary data from the Phase 1/2 study, Moderna is preparing to advance mRNA-1018 into Phase 3. Other pharmaceutical ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of $45.00. The company’s shares closed yesterday ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry witnessed ...